Authors' response
- 1Division of Epidemiology and Public Health, Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham, UK
- 2Department of Gastroenterology, Royal Victoria Infirmary, Newcastle upon Tyne, UK
- 3Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK
- 4Department of Gastroenterology, John Radcliffe Hospital, Oxford, UK
- 5Western General Hospital, Edinburgh, UK
- Correspondence to Professor Richard F A Logan, Epidemiology and Public Health, University of Nottingham, Nottingham, UK; richard.logan{at}nottingham.ac.uk
- Accepted 7 November 2011
- Published Online First 5 December 2011
- Coeliac disease
- gastrointestinal bleeding
- IBD clinical
- gastrointestinal cancer
- Helicobacter pylori
- acid-related diseases
- non-ulcer dyspepsia
- genetic polymorphisms
- gastric neoplasia
- endoscopy
- inflammatory bowel disease
- Crohn's disease
- infliximab
- 5-aminosalicylic acid (5-ASA)
- clinical trials
- endoscopic procedures
We thank Kurien et al for their interest1 in our article.2 Nevertheless, it has to be pointed out that the Sheffield unit did not contribute to the 2007 nationwide UK audit. This is regrettable, because if centres with specialised units had contributed, we would be in a stronger position to debate the value of specialised units. While it seems intuitive that formation of dedicated bleed units should improve outcomes of acute upper gastrointestinal bleeding (AUGIB), whether such units do so remains unclear, given the almost identical endpoints of …
